Dexamethasone for cancer-related fatigue in advanced cancer patients - multi-center phase II trial (Dex8mgPII)
Completed
- Conditions
- A diagnosis of advanced cancer (defined as metastatic or recurrent)
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
A diagnosis of advanced cancer (defined as metastatic or recurrent) with fatigue score 4 and more using NRS(0-10)
20 years and older
Prognosis over 30 days
No anti-cancer treatment plan
Inpatient receiving palliative care
Performance status 1-3
Conprehension of Japanese
Provided written informed consent
Exclusion Criteria
Patients received corticosteroid therapies within 1 week
Patients received surgery within 4 week
Patients received radiation therapy within 2 week
Patients received anti-tumor treatment within 2 week
Patients had diabetes mellitus, active infection and cognitive disorder
Study & Design
- Study Type
- Interventional
- Study Design
- single assignment
- Primary Outcome Measures
Name Time Method - The change of FACIT-Fatigue subscale score at day 8
- Secondary Outcome Measures
Name Time Method